There were no differences between the treatment groups for additional secondary end points , for individual components of the primary end point , or in all-cause mortality ( 371 events in the darapladib group and 395 in the placebo group [ 7.3 % vs 7.1 % at 3 years ; HR , 0.94 [ 95 % CI , 0.82-1 .08 ] ; P = .40 ) .